新一代的流行性乙型腦炎疫苗doc-資料下載頁(yè)
2025-07-18 06:05本頁(yè)面
【正文】 yashida K, et al. Nonclinical and phase Ⅰclinical trials of a Vero cellderived inactivated Japanese encephalitis vaccine. Vaccine, 2003, 21：4519～4526.[14]Chammbers T J, Nestorowicz A, Mason P W, et al. Yellow Fever/Japanese Encephalitis Chimeric Viruses：Construction and Biological Properties. Journal of Virology,1999,73(4)：3095～3101.[15]Guirakhoo F, Zhang Z X, Chambers T J, et al. Immunogenicity, Genetic Stability and Protective Efficacy of a Rebinant, Chimeric Yellow FeverJapanese Encephaliltis Virus(ChimeriVaxJE) as a Live, Attenuated Vaccine Candidate against Japanese Encephalitis. Virology,1999,257：363～372.[16]Monath T P, Soike K, Levenbook I, et al. Rebinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis(SA14142) virus and the capsid and nonstructural genes of yellow fever(17D) virus is safe, immunogenic and protective in nonhuman primates. Vaccine,1999,17：1869～1882.[17]Monath T P, Levenbook I, Soike K, et al. Chimeric Yellow Fever Virus 17DJapanese Encephalitis Virus Vaccine：DoseResponse Effectiveness and Extended Safety Testing in Rhesus Monkeys. Journal of Virology, 2000, 74(4)：1742～51.[18]Monath T P, McCarthy K, Bedford P, et al. Clinical proof of principle for ChimeriVaxTM：rebinant live, attenuated vaccine against flavivirus infections. Vaccine, 2002,20(7～8)：1004～18.[19]Monath T P, Guirakhoo F, Nichols R, et al. Chimeric Live, Attenuated Vaccine against Japanese Encephalitis(ChimeriVaxJE)：Phase 2 Clinical Trials for Safety and Immunogenicity, Effect of Vaccine Dose and Schedule, and Memory Response to Challenge with Inactivated Japanese Encephalitis Antigen. The Journal of Infectious Diseases,2003,188(15,October)：1213～30.10
規(guī)章制度相關(guān)推薦
鄂ICP備17016276號(hào)-1